PMID- 37396101
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230704
IS  - 1754-6605 (Print)
IS  - 1754-6605 (Electronic)
IS  - 1754-6605 (Linking)
VI  - 17
DP  - 2023
TI  - Short-course radiotherapy for rectal cancer: real-world evidence in Argentina.
PG  - 1555
LID - 10.3332/ecancer.2023.1555 [doi]
LID - 1555
AB  - BACKGROUND: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is 
      a recommended strategy in the neoadjuvant setting for resectable locally advanced 
      rectal cancer (LARC), as well as in cases of metastatic disease for local 
      control. There is scarce information regarding the use of SCRT for patients who 
      have received nonoperative management. OBJECTIVES: To describe the 
      characteristics of patients who received treatment with SCRT for LARC and 
      metastatic rectal cancer, toxicity, and the approach after radiation treatment. 
      METHODS: This is a retrospective analysis of all patients who underwent SCRT for 
      rectal cancer at the Alexander Fleming Institute from March 2014 to June 2022. 
      RESULTS: In total, 44 patients were treated with SCRT. The majority were male 
      (29, 66%), with a median age of 59 years (interquartile range 46-73). Most 
      patients had stage IV disease (26, 59.1%), followed by LARC (18, 40.9%). Most 
      lesions were located in the middle rectum (30, 68%). The majority of LARC 
      patients underwent SCRT followed by consolidation chemotherapy (ChT) (16/18, 
      89%), while most patients with metastatic disease underwent SCRT followed by 
      consolidation ChT (14/26, 53.8%). A clinical complete response (cCR) was 
      documented in 8/44, 18.2% of patients. Most patients with LARC and cCR were 
      managed by a watch and wait approach (5/18, 27.7%). Local recurrence was observed 
      in LARC cases (2/18, 11.1%). Patients who underwent SCRT following consolidation 
      ChT were more likely to have adverse events (AEs) than those undergoing induction 
      ChT following SCRT (11/30, 36.7% versus 3/12, 25%, p = 0.02). CONCLUSION: In a 
      subgroup of patients diagnosed with LARC and treated with SCRT followed by ChT, 
      surgical treatment could be omitted after they achieved a cCR. Local recurrence 
      was similar to that reported in a previous study. SCRT is a reasonable option for 
      local disease control in stage IV disease, yielding low toxicity rates. 
      Therefore, decisions must be made by a multidisciplinary team. Prospective 
      studies are necessary to reach further conclusions.
CI  - (c) the authors; licensee ecancermedicalscience.
FAU - Tissera, Natalia S
AU  - Tissera NS
AD  - Upper Gastrointestinal Cancer Translational Research Group, Vall d Hebron 
      Institute of Oncology (VHIO), 08035 Barcelona, Spain.
AD  - https://orcid.org/0000-0002-3396-6878.
FAU - Freile, Berenice
AU  - Freile B
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0003-3192-126X.
FAU - Waisberg, Federico
AU  - Waisberg F
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0003-4435-5068.
FAU - Esteso, Federico
AU  - Esteso F
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0003-1977-9846.
FAU - Galli, Mariana
AU  - Galli M
AD  - Department of Radiotherapy, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0003-0147-2192.
FAU - Loria, Fernando Sanchez
AU  - Loria FS
AD  - Department of Surgery, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0001-9708-0649.
FAU - Luca, Romina
AU  - Luca R
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0001-8564-905X.
FAU - Pedraza, Ivana Ines
AU  - Pedraza II
AD  - Department of Surgery, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0001-9679-8368.
FAU - Enrico, Diego Hernan
AU  - Enrico DH
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0003-4121-6855.
FAU - Chacon, Carolina
AU  - Chacon C
AD  - Department of Radiotherapy, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0009-0004-8556-6325.
FAU - Huertas, Eduardo
AU  - Huertas E
AD  - Department of Surgery, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0003-3473-0928.
FAU - Chacon, Matias Rodrigo
AU  - Chacon MR
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0001-6872-4185.
FAU - O'Connor, Juan Manuel
AU  - O'Connor JM
AD  - Department of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
AD  - https://orcid.org/0000-0002-6975-5466.
LA  - eng
PT  - Journal Article
DEP - 20230601
PL  - England
TA  - Ecancermedicalscience
JT  - Ecancermedicalscience
JID - 101392236
PMC - PMC10310334
OTO - NOTNLM
OT  - Latin America
OT  - clinical complete response
OT  - rectal cancer
OT  - short-course radiotherapy
OT  - watch and wait
COIS- The authors declare no conflict of interest for this manuscript.
EDAT- 2023/07/03 13:06
MHDA- 2023/07/03 13:07
PMCR- 2023/06/01
CRDT- 2023/07/03 11:15
PHST- 2023/04/12 00:00 [received]
PHST- 2023/07/03 13:07 [medline]
PHST- 2023/07/03 13:06 [pubmed]
PHST- 2023/07/03 11:15 [entrez]
PHST- 2023/06/01 00:00 [pmc-release]
AID - can-17-1555 [pii]
AID - 10.3332/ecancer.2023.1555 [doi]
PST - epublish
SO  - Ecancermedicalscience. 2023 Jun 1;17:1555. doi: 10.3332/ecancer.2023.1555. 
      eCollection 2023.